<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02097004</url>
  </required_header>
  <id_info>
    <org_study_id>E+VIP</org_study_id>
    <nct_id>NCT02097004</nct_id>
  </id_info>
  <brief_title>Study of Therapeutic Vaccination With Intensified Schedule Plus Pegasys Dual Therapy on Chronic Hepatitis B Infection</brief_title>
  <acronym>E+VIP</acronym>
  <official_title>Phase4, to Compare Efficacy and Safety of Therapeutic Vaccination With Intensified Schedule Plus Pegylated Interferon Dual Therapy on Seroclearance of HBS Antigen in Patients With Complete Virological Response Induced by Entecavir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, Open label, Single center, Prospective study to compare efficacy and safety of
      Therapeutic Vaccination with Intensified schedule plus Pegylated Interferon dual Therapy on
      Seroclearance of Hepatitis B virus Surface Antigen in Patients with Complete Virological
      Response Induced by Entecavir
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, Open label, Single center, Prospective study to compare efficacy and safety of
      Therapeutic Vaccination with Intensified schedule plus Pegylated Interferon dual Therapy on
      Seroclearance of Hepatitis B virus Surface Antigen in Patients with Complete Virological
      Response Induced by Entecavir (E + VIP)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The rate of HBsAg-seroclearance</measure>
    <time_frame>The rate of HBsAg-seroclearance at the time point of at weeks 72</time_frame>
    <safety_issue>No</safety_issue>
    <description>The rate of HBsAg-seroclearance at the time point of at weeks 72 in the concomitant treatment group and at weeks 100 in the sequential treatment group (24 weeks after termination of treatment)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of HBsAg-seroconversion</measure>
    <time_frame>The rate of HBsAg-seroconversion at weeks 72</time_frame>
    <safety_issue>No</safety_issue>
    <description>The rate of HBsAg-seroconversion at weeks 72 in theconcomitant treatment group and at weeks 100 in the sequential treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change of HBsAg level from baseline</measure>
    <time_frame>The Change of HBsAg level from baseline at weeks 72</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Change of HBsAg level from baseline at weeks 72 in the concomitant treatment group and at weeks 100 in the sequential treatment group</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Concomitant:Pegasys, Euvax B, Baracrude</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peginterferon alfa-2a: once weekly 180 μg subcutaneous injection for 48 weeks
HBV vaccination (Euvax B Inj): 1.0 mL (20 μg) intramuscular injection at 4, 8, 12 and 28 weeks
Continue Entecavir(0.5mg) for 100 weeks(once daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequential:Pegasys, Euvax B, Baracrude</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peginterferon alfa-2a: once weekly 180 μg or weight base dose subcutaneous injection for 48 weeks
HBV vaccination (Euvax B Inj): 1.0 mL (20 μg) intramuscular injection at 52, 56, 60 and 76 weeks
Continue Entecavir(0.5mg) for 100 weeks(once daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>-Continue Entecavir(0.5mg) for 100 weeks(once daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <description>once weekly 180 μg subcutaneous injection for 48 weeks</description>
    <arm_group_label>Concomitant:Pegasys, Euvax B, Baracrude</arm_group_label>
    <arm_group_label>Sequential:Pegasys, Euvax B, Baracrude</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HBV vaccination</intervention_name>
    <description>1.0 mL (20 μg) intramuscular injection at 4, 8, 12 and 28 weeks</description>
    <arm_group_label>Concomitant:Pegasys, Euvax B, Baracrude</arm_group_label>
    <arm_group_label>Sequential:Pegasys, Euvax B, Baracrude</arm_group_label>
    <other_name>Euvax B Inj</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Continue Entecavir(0.5mg) for 100 weeks</description>
    <arm_group_label>Concomitant:Pegasys, Euvax B, Baracrude</arm_group_label>
    <arm_group_label>Sequential:Pegasys, Euvax B, Baracrude</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Baracrude</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 20 and 75 year-old

          2. HBsAg-positive for &gt; 6 months apart (medical history can be alternative)

          3. Currently being treated with entecavir 0.5 mg/day for more than 18 months

          4. Undetectable HBV DNA in serum (&lt;20IU/mL) and HBeAg-negative or positive for &gt; 1year

          5. HBsAg titer &lt; 3,000 IU/mL

          6. ALT&lt;300 IU/L

          7. Signed written informed consent after being instructed about the objective and
             procedure of the clinical study

        Exclusion Criteria:

          1. Patients with decompensated liver cirrhosis, any one of the following ① Serum
             bilirubin &gt; 3 mg/dL

             ② Prothrombin time &gt; 6 seconds prolonged or INR &gt;2.3

             ③ Serum albumin &lt; 2.8 g/dL

             ④ History of ascites, variceal hemorrhage, or hepatic encephalopathy

             ⑤ Child-Pugh score ≥7 (Child-Pugh class B or C)

          2. Patients who have evidence of renal insufficiency defined as serum creatinine&gt;1.5
             mg/dL

          3. Patients with psychological problem including depression

          4. Patients who have previous/current significant co-morbidities including congestive
             heart failure, chronic kidney disease, hematologic disease and malignancy including
             hepatocellular carcinoma(patients with malignancy cured 5 years before screening can
             be enrolled)

          5. Patients with seropositivity for anti-HCV, anti-HDV or anti-HIV

          6. Patients who have excessive alcohol consumption (&gt; 30 g/day)

          7. Patients who have evidence of autoimmune hepatitis, hemochromatosis or Wilson's
             disease

          8. Pregnant or breast feeding females or plan for pregnancy or no contraception

          9. Patients with disease may deteriorate with interferon therapy(eg, autoimmune
             thyroiditis)

         10. Patients who have an psoriasis

         11. Patients who have history of antiviral-resistant HBV after previous treatment with
             oral antiviral agents

         12. Previous diagnosis with immunodeficiency or concomitant treatment of immune
             suppressive agent or previous organ transplantation Recipients

         13. Patients who have a history of hypersensitivity to study drug

         14. Uncontrollable seizure, convulsion and/or central nervous system disorders

         15. Patients with severe bone marrow disorder or with history of hypersensitivity to
             biologic agent such as vaccine.

         16. Neutrophil count &lt; 1,500/mm3 or platelet count &lt; 75,000/mm3 or hemoglobin &lt; 10 g/dl

         17. Patients with Pulmonary disease (in case of history of pulmonary disease with
             complete recovery, enrollment is on investigator's discretion)

         18. Patients who have a fever ≥ 38 °C at the baseline

         19. Patients who have a risk of febrile response or systemic reaction

         20. Patients who the investigator deems inappropriate to participate in this study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoon Jun Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yoon Jun Kim, MD. PhD</last_name>
    <phone>82-2-745-1721</phone>
    <email>yoonjun@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeong-Hoon Lee, MD. PhD</last_name>
    <email>pindra@empas.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University</name>
      <address>
        <city>Seoul</city>
        <zip>ASI|KR|KS013</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 2, 2015</lastchanged_date>
  <firstreceived_date>March 23, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Yoon Jun Kim</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>chronic hepatitis B</keyword>
  <keyword>Pegasys</keyword>
  <keyword>Euvax B</keyword>
  <keyword>Baracrude</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Entecavir</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
